<DOC>
	<DOC>NCT01373086</DOC>
	<brief_summary>This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.</brief_summary>
	<brief_title>LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1. Male and female (postmenopausal or surgically sterile). 2. Age from 18 to 75 years inclusive. 3. Subjects with mildtomoderate uncomplicated essential hypertension, with (not more than 2 in combination) or without prior treatment. 4. Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 36 kg/m2. 1. History or evidence of a secondary form of hypertension, 2. History of cardiovascular disease. Type 1 or type 2 diabetes mellitus. 3. Clinically significant valvular heart disease. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Hypertension,</keyword>
	<keyword>mild hypertension,</keyword>
	<keyword>moderate hypertension,</keyword>
	<keyword>high blood pressure,</keyword>
	<keyword>uncomplicated hypertension.</keyword>
</DOC>